Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Investors may be wondering whether Aveanna Healthcare Holdings at US$7.72 is offering good value right now, or if recent enthusiasm has already been fully reflected in the price.
The stock has moved sharply in the short term, with returns of 14.5% over the past week and 14.9% over the past month, while the year to date performance is down 4.5% and the 1-year return is 28.9%.
Recent coverage has focused on Aveanna Healthcare Holdings as investors reassess home health and care services stocks, paying attention to how these businesses are positioned within the broader healthcare sector. This backdrop helps explain why the share price has seen strong short-term moves alongside a very large gain over three years.
On Simply Wall St’s 6-point valuation framework, Aveanna Healthcare Holdings scores 5 out of 6. Next up is a closer look at how traditional valuation tools compare, and how a more holistic approach at the end of this article can give you a clearer view of what that score really means.
A Discounted Cash Flow, or DCF, model takes projections of a company’s future cash flows and discounts them back to today’s value, aiming to estimate what the stock might be worth right now based on those cash flows.
For Aveanna Healthcare Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve months Free Cash Flow is about $130.24 million. Analysts and Simply Wall St projections show Free Cash Flow in the ten year forecast period ranging from around $125.50 million in 2026 to $180.43 million in 2035, with $151 million projected for 2028. After the explicit analyst forecast horizon, further annual cash flows are extrapolated by Simply Wall St and then discounted back to today in dollar terms.
On this basis, the DCF model arrives at an estimated intrinsic value of $13.95 per share. Compared with the current share price of $7.72, this implies the stock is 44.7% undervalued according to this framework.
Approach 2: Aveanna Healthcare Holdings Price vs Earnings
For profitable companies, the P/E ratio is a useful way to think about value because it links what you pay for the stock to the earnings the business is currently generating. In general, investors tend to accept a higher or lower P/E based on what they expect for future earnings growth and how much risk they see in those earnings.
Aveanna Healthcare Holdings currently trades on a P/E of 6.43x. This sits well below the Healthcare industry average of 22.12x and also below the peer group average of 27.87x. On the surface, that kind of gap can suggest the stock is priced more cautiously than many Healthcare peers.
Simply Wall St’s Fair Ratio for Aveanna Healthcare Holdings is 15.01x. This is a proprietary estimate of what a more typical P/E might look like for this company, after considering factors such as earnings growth profile, profit margins, industry, market cap and key risks. Because it adjusts for these company specific traits, the Fair Ratio can offer a more tailored reference point than a simple comparison with industry or peer averages. Set against this 15.01x Fair Ratio, the current 6.43x P/E points to Aveanna Healthcare Holdings trading at a discount on this measure.
Upgrade Your Decision Making: Choose your Aveanna Healthcare Holdings Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of Aveanna Healthcare Holdings future revenue, earnings and margins to a financial forecast, a Fair Value, and then a simple comparison with the current share price that helps clarify whether you see it as a potential buy, hold or sell. All of this is available within an easy tool on the Community page that updates automatically when new news or earnings arrive. For example, one investor might align with a more optimistic Narrative that points to a Fair Value of about US$12.94 per share, while another might prefer a more cautious Narrative closer to US$7.00. By seeing these side by side you can decide which story best matches your own expectations before making any decision.
For Aveanna Healthcare Holdings, here are previews of two leading Aveanna Healthcare Holdings Narratives:
Gap to Fair Value: about 40% below this bullish fair value based on the latest US$7.72 close.
Revenue Growth Assumption: 5.87% per year
Highlights capacity constrained demand in home healthcare, where payer relationships and the shift away from institutional care are expected to support market share gains.
Sees room for margin expansion and stronger free cash flow as preferred payer conversions, digital investments and acquisitions are built into the model.
Assumes the stock could trade on a materially higher future P/E multiple, with fair value tied to bullish analyst expectations for 2029 earnings, margins and discount rates.
Gap to Fair Value: about 10% above this bearish fair value based on the latest US$7.72 close.
Revenue Growth Assumption: 5.49% per year
Focuses on dependence on government reimbursement and regulatory changes that could pressure revenue stability and margins over time.
Builds in the effect of higher labor costs, healthcare worker shortages and tougher contract terms as potential drags on earnings growth.
Applies a lower future P/E multiple and slightly higher discount rate, with a fair value that sits well below the more optimistic analyst targets.
These two Aveanna Healthcare Holdings Narratives provide a clear bullish and bearish reference point so you can stress test your own view on revenue, margins and the valuation multiple you are comfortable using before making any decision.
To go beyond these previews and see how the full community connects the numbers with long term stories for this stock, To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Aveanna Healthcare Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
